Targeting Metabolic Reprograming in Oncology & Fibrosis
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to advance novel anti-cancer and anti-fibrosis therapies to patients. Our lead molecule, lixumistat (IM156), is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OxPhos) pathway in mitochondria and decreases aberrant cell growth in targeted cancer cells and in fibrosis. Lixumistat (IM156) is the first PC1 inhibitor to complete Phase 1 with good tolerability. ImmunoMet has completed Phase 1 dose escalation and food effect studies in healthy subjects and a dose escalation study in patients with advanced solid tumors. A clinical study to characterize lixumistat (IM156) in patients with advanced pancreatic cancer is ongoing, a patient population whose cancer is considered dependent on OxPhos activity. ImmunoMet was founded in 2015 as a spin-off from HanAll Biopharma, a midsized Korean company, and has raised $34 MM since its inception.